As the pharmaceutical landscape evolves, traditional clinical trial designs are increasingly complemented by innovative, data-driven approaches. Real-world data (RWD) offers the potential to augment trials, simulate patient populations, and generate synthetic control arms. In-silico trials, powered by RWD and advanced analytics, help provide a path to faster, more efficient, and highly informative drug development.
This white paper, authored by Billy Amzal, PhD, Head of Strategic Consulting at Phastar, explores practical applications, value, and emerging regulatory perspectives around in-silico trials, and is illustrated with real-world case studies.
What you’ll learn:
- Value Drivers for in-silico Trials.
- Case studies and lessons learnt.
- Emerging Regulatory and Industry Perspectives.
- Best Practices for Implementation.
Fill in your details to download the white paper:
